New York Times put the Alaska Senate election lawsuit at the center of Monday’s midterms coverage. The Trump administration is suing to delay certification if Dan Sullivan loses because another candidate shares his name.
Eight days before the midterms, the case turns on a simple but disruptive claim: another Dan Sullivan could confuse voters. That is the legal hook the administration is using to ask for a delay in certifying the result.
Dan Sullivan and Alaska
The filing matters because it is aimed at the certification stage, not the ballot itself. If the incumbent GOP senator loses, the lawsuit seeks to slow the formal count-up process in the Alaska Senate election.
Jed Rubenfeld was asked to break down the lawsuit and the likelihood of the Trump administration prevailing in court. His analysis sits in a newsletter that also places the election fight alongside other campaign arguments, including Donald Trump’s warning at a rally in Kentucky earlier this month: “This is the most important midterm in the history of our country.”
The midterms and party loyalty
That same page folds in the broader pressure campaign around the vote. Bernie Sanders called it “the most important midterms in modern history,” while Erick Erickson said he will not be voting for Mike Collins in his home state of Georgia.
Peter Savodnik also discussed Democrats who have endorsed Abdul El-Sayed, including Barack Obama, who rallied for him in Michigan over the weekend. The thread running through all of it is discipline: parties and allies are pushing loyalty hard, and the Alaska lawsuit tries to turn a name match into a procedural roadblock.
Christina Sher’s story gives that pressure a different edge. Her mother has Addison’s, and Sher said she could not get an appointment anywhere in the U.S. to get treatment after the diagnosis, a reminder that the newsletter is pairing election maneuvering with a rare-disease problem that still leaves families searching for care.
Thirty million Americans live with rare diseases that fall through the cracks of U.S. medicine, and Sher’s experience shows how that gap can reach beyond policy talk. In Alaska, the immediate question is narrower: whether the court accepts that one shared name is enough to slow certification if Dan Sullivan loses.
